Notice of Results

RNS Number : 8501N

Ergomed plc

14 August 2017

 

PRESS RELEASE

FOR IMMEDIATE RELEASE

Notice of interim results

London, UK - 14 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, will announce its Interim Results for the six months ended 30 June 2017 on Monday 18 September 2017.

Dr Dan Weng, Chief Executive Officer, and Stephen Stamp, Chief Financial Officer, will host a presentation and conference call for analysts at 9:00am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.

ENDS

Enquiries:

Ergomed plc		Tel: [phone]
Dan Weng (Chief Executive Officer)
Stephen Stamp (Chief Financial Officer)
Numis Securities Limited		Tel: [phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer		Tel: [phone]
Alex Price (Joint Broker)
Consilium Strategic Communications - for UK enquiries		Tel: [phone]
Chris Gardner / Mary-Jane Elliott Ivar Milligan / Philippa Gardner	[e-mail]
MC Services - for Continental European enquiries		Tel: [phone]
Anne Hennecke

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

 

END

 

 

NORGGUCCRUPMPUW